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Summary  The  growing  interest  in  dyssynchrony  and  cardiac  resynchronization  therapy  has
opened the  ﬁeld  of  cardiac  stimulation  to  new  haemodynamic  indications.  French  investigators
have played  a  key  role  in  the  formulation  of  new  concepts,  all  arising  from  clinical  observations,
and the  development  (in  collaboration  with  industry)  and  clinical  evaluation  of  resynchroniza-
tion devices.  This  review  summarizes  recent  knowledge  and  perspectives  pertaining  to  atrial,
atrioventricular  and  ventricular  dyssynchrony  and  resynchronization.  Some  of  these  concepts
have been  validated  by  robust  clinical  evidence,  on  the  basis  of  which  scientiﬁc  recommen-
dations have  been  formulated.  Other  concepts  have  been  less  successful  but  probably  merit
further attention.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
MOTS  CLÉS
Désynchronisation
cardiaque  ;
Résumé  L’intérêt  pour  la  désynchronisation  et  la  resynchronisation  cardiaque  n’a  cessé  de
croître, permettant  d’élargir  le  champ  de  la  stimulation  à  de  nouvelles  indications  hémody-
namiques.  Les  équipes  franc¸aises  ont  joué  un  rôle  moteur  dans  la  déﬁnition  de  ces  conceptsResynchronisation
cardiaque  ;
nouveaux,  tous  nés  de  l’observation  clinique,  dans  la  conception  des  outils  de  resynchronisation
en lien  avec  l’industrie,  et  dans  leur  évaluation  clinique.  Cette  revue  se  propose  de  faire  la
réceStimulation synthèse des  connaissances  
cardiaque  ;
Insufﬁsance
cardiaque
aux trois  étages,  atrial,  atrioven
d’avenir.
© 2012  Elsevier  Masson  SAS.  Tou
Abbreviations: AV, atrioventricular; CRT, cardiac resynchronization th
LV, left ventricular; NYHA, New York Heart Association.
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doi:10.1016/j.acvd.2011.12.004ntes  sur  la  désynchronisation  et  la  resynchronisation  cardiaque
triculaire  et  ventriculaire,  et  de  dresser  quelques  perspectives
s  droits  réservés.
erapy; HF, heart failure; LBBB, left bundle branch block;
served.
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trioventricular dyssynchrony and
esynchronization
he  ﬁrst  cardiac  pacemaker  was  implanted  at  Stockholm’s
arolinska  hospital  in  1958,  for  the  treatment  of  syncope  due
o  complete  AV  block.  The  57-year-old  recipient  survived
or  43  years  thereafter,  consumed  24  pulse  generators,  lived
omfortably  and  remained  active  and  free  from  HF,  despite
he  ventricular  dyssynchrony  caused  by  single-chamber  ven-
ricular  pacing.  Other  less  fortunate  patients  have  not
olerated  the  cardiac  dyssynchrony  due  to  ventricular  pac-
ng.  Identiﬁcation  of  patients  prone  to  developing  cardiac
ysfunction  after  ventricular  pacing  remains  an  important
hallenge  for  clinical  practice.
For  a  quarter  of  a  century,  the  only  indication  for  cardiac
acing  was  the  management  or  prevention  of  symptoms  due
o  bradycardia;  its  adverse  effects  on  cardiac  mechanical
unction,  which  could  not  be  circumvented,  were  over-
ooked.  At  that  time,  the  only  pacing  mode  applicable
as  VVI,  perpetuating  AV  dissociation  and  asynchronous
entricular  contraction.  The  ﬁrst  attempts  at  cardiac  resyn-
hronization  were  made  in  the  1960s,  with  the  advent
f  atrial  synchronous  pacemakers,  followed,  in  1981,  by
he  ﬁrst  DDD  pacing  system.  ‘Physiologic’  stimulation  was
orn,  which  restored  AV  synchrony  and  chronotropic  func-
ion.
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igure 1. A. Long PR haemodynamic syndrome in a patient in NYHA f
he left ventricular (LV) ﬁlling time is markedly foreshortened and the tr
. DDD pacing with a standard 150 ms atrioventricular (AV) delay double
ncreases the aortic ejection ﬂow velocity.C.  Daubert  et  al.
ymptomatic, high-degree, atrioventricular
lock: the prime indication for cardiac pacing
ymptomatic,  high-degree,  AV  block  remains  the  most
revalent  (>  40%)  of  all  pacing  indications.  The  mean  age
f  French  patients  paced  for  this  indication,  usually  due
o  degenerative  disease,  is  80  years  [1].  In  the  presence  of
ormal  sinus  node  function,  a  DDD  pacemaker  restores  the
trial  contribution  to  ventricular  ﬁlling  and  preserves  the
hysiological  heart  rate  adaptation.  An  alternative  choice
s  single-chamber  VVIR  pacing,  which  does  not  eliminate
V  dyssynchrony,  although  it  restores  chronotropic  function
ith  rate-responsive  sensors.
hat  is  the  true  impact  of  atrioventricular
esynchronization  in  clinical  practice?
he  long-debated  question  of  clinical  superiority  of  DDD  pac-
ng  over  VVIR  pacing  has  been  answered  only  recently.  After
 French  controlled  study  failed  because  of  lack  of  sup-
ort  from  the  medical  community  and  its  industrial  partners,
0  years  elapsed  until  the  publication  of  the  UK-PACE  trial,
hich  showed  that,  in  older  patients,  ‘physiologic’  pacing
onferred  no  beneﬁt  compared  with  VVI  or  VVIR  pacing  in
erms  of  overall  survival  (primary  criterion)  or  cardiovas-
ular  morbidity,  including  HF,  cerebral  vascular  accidents,
trial  ﬁbrillation,  etc.  [2].
unctional class III. During sinus rhythm, with a 450 ms PR interval,
ansmitral ﬂow is monophasic due to the lack of atrial contribution.
s the LV ﬁlling time, restores an effective atrial contribution and
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Figure 2. Representative example of atrial resynchronization in a patient with HF with a left ventricular (LV) ejection fraction of 60%.
A. The surface electrocardiogram shows typical, high-degree, interatrial block, conﬁrmed by (B) the endocardial electrograms showing a
140 ms delay between the right atrium (RA) and the left atrium (LA) during sinus rhythm. C. A DDD-biatrial pacing system was implanted,
including an RA lead in the sinus node region, a lead advanced to the mid  coronary sinus (CS) to pace the inferolateral LA and a lead at
the right ventricular (RV) apex to synchronize the system. D. A speciﬁc algorithm synchronized LA pacing upon RA sensing, immediately
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Furthermore,  the  risk/beneﬁt  ratio  was  unfavourable  to
DDD  pacing,  which  was  associated  with  an  8%  rate  of  major,
procedure-related  complications  versus  4%  with  VVI  or  VVIR
pacing.  Despite  being  the  land  of  Descartes,  France  paid
little  attention  to  these  observations  and  the  proportion  of
DDD/DDDR  pacing  systems  continued  to  increase  steadily,
reaching  75%  of  implants  in  2009  [1]!
Patients with a symptomatic long PR  interval
may beneﬁt from atrioventricular
resynchronization
A  subgroup  of  highly  incapacitated  patients  owe  their  dis-
ability  and  symptoms  to  a  markedly  prolonged  PR  interval,
which,  as  a  result  of  non-adaptation  to  exercise,  causes  left
heart  mechanical  AV  dyssynchrony,  which  increases  propor-
tionally  to  heart  rate  acceleration  [3].  A  typical  example  at
rest  is  illustrated  in  Fig.  1.  When  properly  selected,  these
patients  derive  a  major  functional  beneﬁt  from  DDD  pac-
ing,  despite  the  ventricular  dyssynchrony  it  creates.  This
haemodynamic  indication  has  been  included  as  a  class  IIa
recommendation  in  the  practice  guidelines  issued  by  inter-
national  professional  societies  [4].
(
n
t
ntrial dyssynchrony and resynchronization
isorders  that  cause  progressive  left  atrial  dilatation,  such
s  long-standing  hypertrophic  cardiomyopathy  and  hyper-
ensive  heart  disease,  are  often  associated,  during  sinus
hythm,  with  major  intra-atrial  conduction  abnormalities.
he  most  extreme  form  is  complete  interatrial  block,  with
 waves  more  than  120  ms  in  duration,  opposite  axes  of
he  initial  vectors  reﬂecting  normal  activation  of  the  right
trium  and  late  vectors  reﬂecting  retrograde  and  delayed
ctivation  of  the  left  atrium  (Fig.  2A).  These  patients  are
t  high  risk  of  atrial  tachyarrhythmias  —mainly  left  atrial
utter  and  HF  [5].  LV  ejection  fraction  in  usually  preserved
r  only  slightly  impaired  in  these  patients.  This  atrial
yssynchrony  can  be  remedied  by  biatrial  stimulation,
hich  implies  the  implantation  of  a  coronary  sinus  lead
o  stimulate  the  lateral  or  posterolateral  wall  of  the  left
trium  [6].  Atrial  resynchronization  devices  have  been
uilt,  along  with  an  algorithm,  to  sense  sinus  activity  in  the
ight  atrium  and  trigger  synchronous  left  atrial  stimulation
Fig.  2C).  It  became  readily  apparent  that  atrial  resynchro-
ization  improves  AV  synchrony  in  the  left  heart  as  well  as
he  global  mechanical  performance  of  hypertrophied  and
on-compliant  left  ventricles  (Fig.  3).
294  C.  Daubert  et  al.
Figure 3. Haemodynamic beneﬁt conferred by atrial resynchronization in a patient who received atrioventricular (AV) sequential pacing
at 70 beats per minute with a standard, 150 ms AV delay. The effects of the switch from single right atrium (RA) DDD pacing to biatrial DDD
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aacing is shown on the left. The abbreviated and monophasic ﬂow 
s soon as atrial resynchronization is reactivated. The effect on the
hown on the right.
The  clinical  usefulness  of  atrial  resynchronization  has
emained  unproven  despite  results  of  long-term  observa-
ional  studies  suggesting  clinical  beneﬁt  [7].  The  negative
esults  of  SYNBIAPACE  [8]—  the  only  controlled,  crossover
tudy  of  atrial  resynchronization  conducted  in  the  early
990s  —  were  never  published.  It  should,  however,  proba-
ly  be  pursued.  SYNBIAPACE  was  methodologically  weak  and
sed  atrial  ﬁbrillation  burden  as  a  primary  study  endpoint,
hen  the  expected  clinical  beneﬁt  was  haemodynamic
nstead  of  antiarrhythmic.  We  will  follow  with  much  interest
he  imminent  revival  of  a  controlled  study  by  other  French
nvestigators,  who  will  examine  the  effects  of  atrial  resyn-
hronization  in  HF  in  the  presence  of  a  preserved  ejection
raction  [9].
entricular dyssynchrony and
esynchronization
hree  different  concepts  will  be  discussed:  prevention
f  ventricular  dyssynchrony,  deliberate  ventricular  dyssyn-
hrony  and  ventricular  resynchronization.
revention of ventricular dyssynchrony
ver  50%  of  approximately  60,000  pacemakers  implanted
nnually  in  France  are  used  to  treat  isolated  sinus  dysfunc-
ion  or  bradycardia-tachycardia  syndrome  [1].  Nearly  all  of
hese  patients  are  paced  incessantly  at  the  atrial  level,
ither  in  single-chamber  AAI-AAIR  mode,  if  AV  conduction
s  preserved,  or  in  dual-chamber  DDD-DDDR  mode,  which  is
onsidered  safer  but  is  associated  with  a  risk  of  unneces-
ary  and  deleterious  asynchronous  ventricular  pacing.  In  the
arly  1990s,  two  mechanistic  studies  compared  the  effects
f  DDD  pacing  with  ventricular  capture  versus  atrial  pacing
lone,  in  recipients  of  dual-chamber  pacemakers  implanted
or  sinus  node  dysfunction  [10,11].  These  studies  showed
hat  asynchronous  activation  due  to  ventricular  capture
aused  considerable  degradation  of  global  and  septal  LV
unction,  accentuated  by  exercise.
Subsequent  observational  and  controlled  clinical  studies
onﬁrmed  the  suspicion  of  long-term  adverse  effects  and
c
t
hg single-atrium pacing doubles in duration and returns to biphasic
ic ejection ﬂow of reversing the order from biatrial to RA pacing is
igher  morbidity  and  mortality  caused  by  ‘forced’  ventric-
lar  pacing  [12,13].  To  prevent  unnecessary  ventricular
apture,  state-of-the  art  pacing  systems  incorporate  spe-
iﬁc  algorithms  that  conﬁne  pacing  to  the  atrial  level,  as
ong  as  intrinsic  AV  conduction  is  preserved.  AAI  SafeR,  the
rst  such  algorithm,  was  developed  in  France.  The  clinical
erit  of  one  these  algorithms  was  conﬁrmed  in  a  large
ontrolled  trial,  which  revealed  a  decreased  incidence  of
trial  ﬁbrillation  in  particular  [14].
eliberate ventricular dyssynchrony: the
articular case of obstructive, hypertrophic
ardiomyopathy
bstructive,  hypertrophic  cardiomyopathy  is  the  only
ardiac  disorder  that  might  beneﬁt  from  ventricular  dyssyn-
hrony.  Original  clinical  observations  were  made  in  France
y  Gilgenkrantz  et  al.  in  the  1960s  [15]. Pre-excitation  of  the
ight  ventricular  apex  reverses  septal  activation  and  delays
he  systolic  thickening  of  the  basal  septum,  decreasing  or
liminating  the  systolic  obstruction  (Fig.  4).  This  effect
equires  the  coexistence  of  complete  ventricular  capture,
anifest  on  the  electrocardiogram  by  the  widest  paced  QRS,
nd  the  preservation  of  normal  AV  synchrony  in  the  left  heart
o  promote  optimal  atrial  contribution.
In  this  disorder,  ventricular  ﬁlling  is  highly  dependent  on
trial  function.  The  effective  attainment  of  both  conditions
s  challenging.  In  the  majority  of  patients,  particularly  in
he  young,  the  PR  interval  during  sinus  rhythm  is  short,
orcing  the  programming  of  an  AV  delay  as  short  as  30—50  ms
n  order  to  capture  the  ventricles  during  DDD  pacing.  This
ight  result  in  a  loss  of  atrial  contribution,  negating
he  beneﬁts  expected  from  ventricular  dyssynchrony  and
xplaining  its  many  apparent  failures.  Modulation  of  AV
unctional  conduction  by  the  prescription  of  pharmaceuti-
als  with  negative  dromotropic  properties,  or  by  catheter
blation,  enables  a  lengthening  of  the  PR  interval  and  the
onversion  of  apparent  treatment  failures  to  secondary
herapeutic  successes  (Fig.  5)  [16].
In  contrast  to  septal  surgical  myectomy  [17,18]  and  alco-
ol  ablation  [19—21], DDD  pacing  is  the  only  treatment
Cardiac  resynchronization  therapy  295
Figure 4. Immediate haemodynamic effects of VDD pacing in hypertrophic obstructive cardiomyopathy. The baseline left intraventricular
gradient is 80 mmHg. As soon as pacing begins, the gradient decreases to 20 mmHg until an atrial extrasystole (APC) occurs, followed by
a long cycle and ventricular paced escape. The postextrasystolic potentiation and transient atrioventricular (AV) dissociation bring the
obstruction back with a gradient of 120 mmHg. The normal function of the pacemaker returns and the gradient gradually decreases over
the following cycles. AV: atrioventricular.
Figure 5. Importance of optimal atrioventricular (AV) synchrony in the left heart, in hypertrophic obstructive cardiomyopathy treated
with DDD pacing. In this 33-year-old patient, whose intrinsic PR was 80 ms in duration, a 30 ms AV delay had be programmed to completely
capture the ventricle from the right ventricular apex. On the left, DDD pacing had no effect on the obstruction. The mitral ﬂow is impaired,
with a markedly delayed and barely visible atrial contribution. The images on the right were obtained after modulation of AV junctional
conduction by radiofrequency energy, lengthening the intrinsic PR interval to 220 ms and allowing the reprogramming of the pacemaker
AV delay (AVD) to 150 ms. The return of a biphasic mitral ﬂow is associated with an effective atrial contribution and disappearance of the
subaortic gradient. LVOT: left ventricular outﬂow tract.
296  C.  Daubert  et  al.
Figure 6. Ventricular resynchronization by DDD-biventricular stimulation. This patient was in New York Heart Association (NYHA) heart
failure (HF) functional class III despite optimal medical management. A. He was in sinus rhythm, with a left ventricular (LV) ejection fraction
of 25%, a QRS complex duration of 170 ms and typical left bundle branch block (LBBB) morphology; a 190 ms delay was measured between the
onset at the right ventricular (RV) septum and the end of ventricular activation at the lateral LV wall. B. A triple-chamber pulse generator
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has implanted and interfaced with a right atrial lead to synchroniz
ree wall and an LV lead placed in a posterolateral tributary of the 
uration immediately shortened to 120 ms. IEGM: intracardiac elec
f  obstructive,  hypertrophic  cardiomyopathy  that  has  been
ompared  with  medical  management  in  controlled  studies
22,23].  While  a  signiﬁcant  decrease  in  transaortic  gradient
as  measured,  along  with  the  alleviation  of  symptoms  and
mproved  quality  of  life,  the  maximal  duration  of  exercise
the  primary  study  endpoint)  did  not  change  signiﬁcantly
nd  a  placebo  effect  of  device  implantation  was  strongly
uspected  (Fig.  6)  [24].
Consequently,  this  treatment  has  been  assigned  a  class
Ib/level  of  evidence  B  recommendation  in  the  practice
uidelines  issued  by  international  professional  societies
4].  Should  it  be  abandoned  altogether?  We  believe  not  and
ecommend  its  re-evaluation,  using  robust  methodology
nd  optimal  delivery  of  individual  therapy,  which  was  far
rom  the  case  in  the  PIC  and  M-Pathy  trials.  Furthermore,
y  adding  a  cardioverter  deﬁbrillator,  a  comprehensive
lectrical  treatment  can  be  offered,  which  relieves  the
ubaortic  obstruction  and  prevents  arrhythmic  sudden
eath,  unlike  isolated  myectomy  or  septal  ablation  [25].entricular resynchronization in heart failure
he  idea  of  ventricular  resynchronization  as  a  treatment  for
F,  arising  from  clinical  and  epidemiological  observations
e
t
1
tentricular stimulation with sinus activity, an RV lead placed at the
ary sinus (CS). C. When stimulation was turned on (arrow) the QRS
am channel; RA: right atrium.
vailable  in  the  early  1990s,  is  attributed  to  Cazeau  et  al.
26]. LBBB  is  present  in  up  to  30%  of  patients  presenting  with
ystolic  cardiac  dysfunction,  and  QRS  and  PR  duration  both
ncrease  as  LV  dysfunction  and  HF  progress.  LBBB  is  an  inde-
endent  predictor  of  death.  In  addition,  echocardiographic
bservations  by  Grines  et  al.  revealed  an  alteration  of  sys-
olic  performance  and  LV  ﬁlling  due  to  isolated  LBBB,  which
auses  dyssynchrony  of  contraction  and  relaxation  (Fig.  7)
27].
The  results  of  the  ﬁrst  short-term,  haemodynamic  studies
f  biventricular  or  LV  stimulation  were  highly  encouraging
28—30].  Compared  with  baseline,  stimulation  immedi-
tely  lowered  the  pulmonary  pressures  and  increased
ardiac  output  and  pulse  pressure.  Subsequently,  more
etailed  investigations  revealed  that  biventricular  stimula-
ion  increases  contractile  function  and  improves  overall  LV
erformance  without  increasing  energetic  demand,  in  con-
rast  to  the  administration  of  inotropes  [31—33]. At  the  same
ime,  the  implantation  of  permanent  CRT  systems  began  in
umans,  to  stimulate  the  left  ventricle  via  a  transthoracic,
picardial  approach  [26,34]  or  via  the  coronary  venous  sys-
em  [35]. Observational  studies  conducted  throughout  the
990s  conﬁrmed  the  feasibility  and  relative  safety  of  the
echnique  despite  the  use  of  rudimentary  instrumentation.
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Figure 7. Immediate haemodynamic effects of ventricular resynchronization. Atrial only stimulation and intrinsic atrioventricular (AV)
conduction with left bundle branch block (LBBB) and a very wide QRS complex is compared with atriobiventricular stimulation at the same
heart rate. The onset of resynchronization (red arrow) is followed by an immediate fall in pulmonary capillary wedge pressure (PCWP) from
35 to 20 mmHg along with systolic peak disappearance, a 33% increase in cardiac output (CO) and a 30 mmHg increase in pulse pressure. BP:
Q
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The  proof  of  concept  was  ﬁnally  obtained  in  2001,  in
the  multicentre,  crossover,  controlled  MUSTIC  trial,  which
showed  that,  compared  with  no  stimulation,  biventricu-
lar  stimulation  signiﬁcantly  increased  the  distance  covered
during  a  hall  walk  test,  improved  quality  of  life  and  low-
ered  the  mean  NYHA  functional  class  in  a  population  of
patients  presenting  in  HF  functional  class  III  or  IV  [36].
Since  then,  clinical  evidence  has  continued  to  accumulate,
with  the  publication  between  2001  and  2010  of  remarkably
concordant  results  from  over  a  dozen  controlled  clinical  tri-
als  that  included  more  than  8000  patients.
The  main  investigative  steps  have  been:  the  conﬁrmation
of  a  decrease,  conferred  by  CRT  alone,  in  long-term  car-
diovascular  morbidity  and  mortality,  all-cause  mortality  and
rate  of  sudden  death  in  patients  in  NYHA  functional  class  III
[37,38];  and  the  conﬁrmation,  in  the  recent  REVERSE,  MADIT
and  RAFT  trials,  of  the  prevention  of  progression  of  HF  and
of  ventricular  remodelling in  patients  in  NYHA  functional
class  II  [38—42]. This  robust  evidence  prompted  the  Euro-
pean  Society  of  Cardiology  to  assign,  in  2006,  a  class  I/level
of  evidence  A  to  CRT  for  patients  presenting  in  NYHA  func-
tional  classes  III  or  IV  and,  in  2010,  for  patients  presenting  in
NYHA  functional  class  II  after  unsuccessful  optimal  medical
management  and  with  an  LV  ejection  fraction  less  than  35%
and  a  QRS  complex  more  than  150  ms  [43].
With  respect  to  the  electrocardiographic  criteria,  it  is
noteworthy  that  the  REVERSE,  MADIT-CRT  and  RAFT  trials
underscored  the  importance  of  the  duration  and  morphology
of  the  QRS  complex.  In  all  three  trials,  the  beneﬁt  con-
ferred  by  CRT  was  limited  to  patients  with  LBBB  or  whose
t
r
w
TRS  duration  was  more  than  150  ms.  Although  these  were
ubgroup  analyses,  the  level  of  evidence  was  sufﬁcient  to
imit  the  clinical  indication  to  these  populations  who  were
ighly  likely  to  respond  to  treatment.  These  are  probably
he  ﬁrst  treatment  recommendations  made  by  an  interna-
ional  professional  society  that  were  not  strictly  based  on
rimary  study  endpoints  and  the  inclusion  criteria  applied  in
he  studies  that  were  used  for  their  formulation  —  probably
n  important  stage  in  the  history  of  clinical  guidelines.
uture endeavours
uch  has  been  accomplished,  although  much  remains  to
e  done.  Important  issues  that  remain  unsettled,  such  as
trial  resynchronization  and  electrical  treatment  of  hyper-
rophic,  obstructive  cardiomyopathy,  must  be  revisited  using
ew  tools  and  more  rigorous  methodologies.  Despite  a  strict
election  of  a  small  proportion  of  patients  with  HF,  the  rate
f  response  to  CRT  does  not  exceed  70%,  illustrating  the  cur-
ent  limitations  of  the  patient  selection  criteria  as  well  as
f  the  techniques  of  stimulation.  While  the  potential  power
f  the  electrocardiogram  remains  underestimated,  it  is  not
he  only  tool  available.  Imaging  techniques,  which  have  lost
omentum  since  the  inconclusive  results  of  the  PROSPECTrial  [44], will  likely  return  with  new,  more  sensitive,  more
eproducible  and  less  operator-dependent  techniques,  along
ith  a  more  global  perspective  of  mechanical  dyssynchrony.
hese  new  instruments  will  need  to  be  rigorously  evaluated.
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Today’s  CRT  is  based  on  a  simple  (perhaps  even  simplistic)
oncept,  which  might  be  the  key  to  its  success.  Dual-point,
ight  to  LV  stimulation  lacks  power  and  is  unlikely  to  provide
ptimal  resynchronization  in  the  majority  of  patients.  New
onﬁgurations  and  technological  progress  must  be  tested,
eaving  aside  individual  and  poorly  reproducible  options.
fter  the  resolution  of  several  technical  challenges,  LV  endo-
ardial  stimulation  should  logically  replace  the  electrically
nd  mechanically  less  effective  epicardial  stimulation.  It
emains  to  be  shown,  however,  whether  more  complex  con-
gurations  will  yield  better  results.  We  must  keep  in  mind
hat  the  merit  of  a  technique  is  not  strictly  gauged  by  its
herapeutic  efﬁcacy  but  also  by  its  feasibility  and  the  risks
ncurred  by  the  patients.
Finally,  new  clinical  indications  for  CRT  will  be  evaluated,
lthough  might  not  be  validated.  Prior  experience  has  shown
hat  casting  a  wider  and  wider  net  tends  to  decrease  the
eneﬁts  conferred  by  a  given  technique.  Prospective  indi-
ations  include  NYHA  functional  class  I,  echocardiographic
yssynchrony  in  the  absence  of  a  wide  QRS,  the  so-called
Narrow  QRS’,  standard  pacing  with  a  presumed  high  per-
entage  of  ventricular  capture,  HF  with  LBBB  but  no  severe
V  dysfunction  and  HF  with  a  preserved  LV  ejection  fraction,
lthough  the  last  of  these  seems  less  likely.
We  wish  much  success  to  all  who  will  pursue  this  trail  of
dventures.
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